Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2008

Fujiwara Yoshiro, Kiura Katsuyuki, Toyooka Shinichi, Hotta Katsuyuki, Tabata Masahiro, Takigawa Nagio, Soh Junichi, Tanimoto Yasushi, Kanehiro Arihiko, Kato Katsuya, Date Hiroshi, Tanimoto Mitsune

Abstract excerpt

PURPOSE: The factors affecting survival after gefitinib treatment in patients with non-small cell lung cancer (NSCLC) remain to be fully elucidated, although epidermal growth factor receptor (EGFR) mutation is a substantial prognostic factor. KL-6 has been studied as a useful indicator for inters...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Mucin-1

Share to Prognosis

Share to Quinazolines

Source

Identifiers

PMID: 17765355
DOI: 10.1016/j.lungcan.2007.07.018

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17765355-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.PMID 17765355Read ↗

Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.Semantic proximity Read ↗

Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels.Semantic proximity Read ↗

Use of serum KL-6 level for detecting patients with restrictive allograft syndrome after lung transplantation.Semantic proximity Read ↗

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.Semantic proximity Read ↗

Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.Semantic proximity Read ↗

A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B.Semantic proximity Read ↗

Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis.Semantic proximity Read ↗

Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.